Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 1Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 61Prostatic Neoplasms 43Lung Neoplasms 35Multiple Myeloma 34Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 22Colorectal Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Neoplasm Metastasis 19Ovarian Neoplasms 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Leukemia, Myeloid, Acute 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Nasopharyngeal Carcinoma 11Myasthenia Gravis 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Melanoma 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7

Interventions

exemestane 1Tamoxifen 1Neoadjuvant Therapy 1Letrozole 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Intraductal, Noninfiltrating × 30 days × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡